FDA
FDA approves Otarmeni, the first gene therapy for congenital hearing loss—to be offered free to patients
On April 23, 2026, FDA granted accelerated approval to Otarmeni (lunsotogene parvec‑cwha), the first gene therapy for pediatric and adult patients with severe‑to‑profound congenital sensorineural hearing loss (any frequency >90 dB HL) caused by biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.
FDA‑approved gene therapies in the U.S. have typically launched with one‑time list prices ranging from roughly $850,000 to more than $4 million per patient, raising long‑standing concerns about affordability. Notably, Regeneron announced it will provide Otarmeni free of charge to clinically eligible U.S. patients, a move that could significantly expand real‑world access to this highly specialized therapy.
Genetic mutations underlie approximately half of congenital hearing loss cases, with OTOF variants responsible for an estimated 2% to 8% of inherited non‑syndromic cases. Loss of functional otoferlin disrupts auditory signal transmission, and delayed diagnosis can limit early intervention, increasing the risk of persistent speech and language delays.
Otarmeni is a dual adeno-associated virus (AAV) vector-based gene therapy administered as a single intracochlear infusion, using a surgical approach similar to cochlear implantation. The therapy delivers a functional copy of the OTOF gene to inner hair cells, restoring otoferlin production and synaptic auditory signaling.
Accelerated approval was supported by data from the ongoing CHORD phase 1/2 trial, enrolling infants and children aged 10 months to 16 years. Among 20 evaluable participants, 80% achieved clinically meaningful hearing improvement by 24 weeks, meeting the primary endpoint of achieving hearing thresholds ≤70 dB HL by pure‑tone audiometry. Objective confirmation showed 70% achieved auditory brainstem responses ≤90 dB, and with longer follow‑up, 42% attained normal hearing levels, including perception of whispers (≤25 dB HL). Continued approval is contingent on confirmatory data demonstrating durability and benefits on speech development and quality of life.
The most common adverse reactions reported in ≥5% of patients were otitis media, vomiting, nausea, dizziness, procedural pain, gait disturbance, and nystagmus. Providers should monitor for surgical complications.
“The FDA approval of Otarmeni signals a new era in the treatment of genetic forms of hearing loss, where reinstating 24/7 natural hearing is now possible,” said A. Eliot Shearer, MD, PhD, otolaryngologist at Boston Children’s Hospital, Associate Professor of Otolaryngology-Head and Neck Surgery at Harvard Medical School, and a CHORD trial investigator. “I’ve witnessed firsthand my trial participant responding to their mother’s voice, dancing to music and interacting with the world, and these moments are now possible for more children born with this specific form of hearing loss.”
By pairing a one‑time gene therapy with no‑cost access, this approval shifts the treatment paradigm for OTOF‑related congenital hearing loss beyond lifelong device dependence toward disease‑modifying care.
Sources:
U.S. Food and Drug Administration. (2026, April 23). News release. FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
Regeneron. (2026, April 26). Press release. Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Wong CH, et al. (2023, November 8). Gene Therapy. The estimated annual financial impact of gene therapy in the United States